X

Trial Profile

Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary)
Indications Amyotrophic lateral sclerosis
Focus Pharmacodynamics
Acronyms IMODALS

Most Recent Events

28 Apr 2017 Primary endpoint (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in percentage of total lymphocytes) has been met.
28 Apr 2017 Primary endpoint (Cell count (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in number) has been met.
28 Apr 2017 Preliminary results presented at the 69th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com